Cargando…

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial

The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a 31.2% efficacy rate. Plasma specimens from vaccine and placebo recipients were used in an extensive set of assays to identify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zolla-Pazner, Susan, deCamp, Allan C., Cardozo, Timothy, Karasavvas, Nicos, Gottardo, Raphael, Williams, Constance, Morris, Daryl E., Tomaras, Georgia, Rao, Mangala, Billings, Erik, Berman, Phillip, Shen, Xiaoying, Andrews, Charla, O'Connell, Robert J., Ngauy, Viseth, Nitayaphan, Sorachai, de Souza, Mark, Korber, Bette, Koup, Richard, Bailer, Robert T., Mascola, John R., Pinter, Abraham, Montefiori, David, Haynes, Barton F., Robb, Merlin L., Rerks-Ngarm, Supachai, Michael, Nelson L., Gilbert, Peter B., Kim, Jerome H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547933/ https://www.ncbi.nlm.nih.gov/pubmed/23349725 http://dx.doi.org/10.1371/journal.pone.0053629

Ejemplares similares

Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
por: Ratto-Kim, Silvia, et al.
Publicado: (2015)

ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone
por: Costanzo, Margaret C., et al.
Publicado: (2023)

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011)

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
por: Kim, JH, et al.
Publicado: (2009)

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees
por: Yates, Nicole L., et al.
Publicado: (2018)

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor
por: Peachman, Kristina K., et al.
Publicado: (2015)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
por: Fischinger, Stephanie, et al.
Publicado: (2020)

Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
por: Herrera, Carolina, et al.
Publicado: (2022)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
por: Easterhoff, David, et al.
Publicado: (2020)

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
por: Choi, Ickwon, et al.
Publicado: (2015)

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand
por: Kaewkungwal, J, et al.
Publicado: (2009)

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
por: Gottardo, Raphael, et al.
Publicado: (2013)

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site
por: McLellan, JS, et al.
Publicado: (2012)

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis
por: Wills, Saintedym, et al.
Publicado: (2018)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
por: Nicely, Nathan I., et al.
Publicado: (2015)

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
por: Zolla-Pazner, Susan, et al.
Publicado: (2014)

Antibody responses to V2 loop are induced by CRF01_A E and not Clade B envelopes
por: Karasavvas, N, et al.
Publicado: (2012)

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection
por: Zolla-Pazner, Susan, et al.
Publicado: (2014)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
por: Akapirat, Siriwat, et al.
Publicado: (2018)

Aggregate complexes of HIV-1 induced by multimeric antibodies
por: Stieh, Daniel J, et al.
Publicado: (2014)

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
por: Karnasuta, Chitraporn, et al.
Publicado: (2017)

Pre-existing humoral immunity in military smallpox vaccinees temporally effects MVA-vectored transgene expression in dendritic cells
por: Ngauy, V, et al.
Publicado: (2012)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
por: Karasavvas, Nicos, et al.
Publicado: (2015)

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection
por: Auclair, Sarah, et al.
Publicado: (2018)

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2019)

Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response
por: Williams, LaTonya D., et al.
Publicado: (2023)

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination
por: Tomalka, Jeffrey Alan, et al.
Publicado: (2021)

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection
por: Wang, Yufei, et al.
Publicado: (2017)

A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination
por: Lemke, Melissa M., et al.
Publicado: (2021)

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2020)

Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
por: Vaccari, Monica, et al.
Publicado: (2019)

Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1
por: Shangguan, Shida, et al.
Publicado: (2021)

A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcγR Complex Formation After Vaccination
por: Lemke, Melissa M., et al.
Publicado: (2022)

An HIV Vaccine for South-East Asia—Opportunities and Challenges
por: Pitisuttithum, Punnee, et al.
Publicado: (2013)

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women
por: Gilbert, Peter B., et al.
Publicado: (2017)

P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
por: Pitisuttithum, P, et al.
Publicado: (2009)

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144
por: Perez, Lautaro G., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f8rrsv32ufmrqnhl0i1cnksefq